Inscripta, Inc.
- Industry
- Biotechnology
- Founded Year
- 2015
- Headquarters
- Pleasanton, California, United States
- Employee Count
- 140
Key People
- Sri Kosaraju - President and Chief Executive Officer
- John Stuelpnagel - Chairman of the Board
- Kristala Prather - Board of Directors
- Bryan Roberts - Board of Directors
- Jim Tananbaum - Board of Directors
- Roger Wyse - Board of Directors
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in MedTech and biotechnology.
The leadership includes individuals like John Stuelpnagel, co-founder of Illumina, and Sri Kosaraju, former President of Penumbra, indicating a strong foundation in MedTech entrepreneurship.
- Clinical Need
-
Aspect: Very Strong
Summary: Inscripta addresses a significant need in genome engineering with its scalable digital genome engineering platform.
The Onyx platform enables massively parallel, trackable editing of single cells, fulfilling a strong clinical need for advanced genome engineering solutions.
- Competition
-
Aspect: Somewhat crowded
Summary: The genome engineering market has several players, but Inscripta's unique platform offers a competitive edge.
Competitors like Horizon Discovery and Integrated DNA Technologies are present, but Inscripta's fully automated benchtop platform provides a distinct advantage.
- Technical Challenge
-
Aspect: Predictable
Summary: The development of the Onyx platform involves complex but manageable technical challenges.
The integration of CRISPR-based technologies into a benchtop platform requires sophisticated engineering, but the company's expertise suggests these challenges are predictable.
- Patent
-
Aspect: Very Strong
Summary: Inscripta holds a robust patent portfolio supporting its genome engineering technologies.
With over 200 patents, Inscripta's intellectual property provides a significant barrier to entry for competitors.
- Financing
-
Aspect: Well-funded
Summary: The company has secured substantial funding from reputable investors.
Inscripta has raised a total of $417.5 million over six funding rounds, indicating strong investor confidence.
- Regulatory
-
Aspect: 510k/PMA
Summary: The Onyx platform requires regulatory approval, which is a standard process for medical devices.
As a genome engineering tool, the Onyx platform will undergo regulatory review to ensure safety and efficacy, a typical requirement in the biotechnology industry.
Opportunity Rollup
- Odds of Success
- 3.8
- Peak Market Share
- 4.85
- Segment CAGR
- 10.7%
- Market Segment
- Genome Engineering
- Market Sub Segment
- Digital Genome Engineering Platforms
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.73 |
| 3 | 1.70 |
| 4 | 3.40 |
| 5 | 4.85 |
Key Takeaway
Inscripta's innovative Onyx platform positions the company as a leader in the growing genome engineering market, supported by a strong team and substantial funding.